Late Stage Chronic Kidney Disease Drugs Market Forecast & Growth | 2031

The late stage chronic kidney disease drugs market size was estimated to be US$ 5.74 billion in 2021 and US$ XX billion in 2023 and is expected to reach US$ 17.95 billion by 2031; it is estimated to record a CAGR of 12.2% in 2023–2031. The high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy are driving factors. Introducing new preclinical models to improve target validation and understand disease development will likely remain key to late stage chronic kidney disease drug market trends.

Late Stage Chronic Kidney Disease Drugs Market Analysis

The WHO has projected various strategies to support policy-makers in developing suitable policies, including the concept of the vital medicine list and the universal health coverage (UHC) approach. Moreover, European countries with advanced UHC and social protection systems have developed pharmaceutical pricing and reimbursement systems that intend to offer various crucial medicines to their citizens at no or reduced cost. Furthermore, under the ESRD PPS for CY 2024, Medicare expects to pay $6.7 billion to approximately 7,900 ESRD facilities for furnishing renal dialysis services. The final CY 2024 ESRD PPS base rate is US$271.02, an increase of US$5.45 to the current CY 2023 base rate of US$265.57.

Late Stage Chronic Kidney Disease Drugs Market Overview

Asia Pacific is the fastest-growing market for late stage chronic kidney disease drugs. The growth is mainly urged by the increasing number of ESRD patients and the growing prevalence of diabetes & hypertension (major causes of kidney failure). In Asia Pacific countries, patients with early-stage CKD progress to end-stage renal disease (ESRD), dependent on renal replacement therapy at a different rate. CKD has continued to increase among the leading causes of death worldwide because of aging and an increasing burden of risk factors for CKD, including diabetes and hypertension.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Late Stage Chronic Kidney Disease Drugs Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Late Stage Chronic Kidney Disease Drugs Market Drivers and Opportunities

High Prevalence of Diseases Leading to Chronic Kidney Diseases

The National Library of Medicine states that chronic kidney disease (CKD) is recognized as a leading public health problem worldwide. Globally, the estimated prevalence of CKD is 13.4%, and patients with end-stage kidney disease (ESKD) requiring renal replacement therapy are estimated to be between 4.902 and 7.083 million. Furthermore, the Centers for Disease Control and Prevention (CDC) published that in the US, More than 1 in 7 US adults, or 35.5 million people, or 14% are estimated to have CKD. Also, 9 in 10 adults with CKD are unaware of it.

Introduction of New Late Stage Chronic Kidney Disease Drugs – An Opportunity

Manufacturers are focusing on adopting strategies such as product launches and approvals, R&D investments, government funding, and partnerships to develop new drugs and provide easy access for patients worldwide. For instance, in April 2021, the U.S. Food and Drug Administration approved Farxiga (dapagliflozin) oral tablets to decrease the risk of declined kidney function, , cardiovascular death, kidney failure, and other problems related to chronic kidney disease who are at risk of disease progression.

The adoption of drugs has increased significantly across various North American, European, and Asian countries.

Late Stage Chronic Kidney Disease Drugs Market Report Segmentation Analysis

Key segments that contributed to the derivation of the late-stage chronic kidney disease drugs market analysis are product type, indication,  and distribution channel.

• Based on the product type, the late stage chronic kidney disease drugs market is segmented into vitamin D, calcium-based phosphate binders, potassium binders, calcimimetics, and others. The calcimimetics segment held the largest market share in 2023, and the same segment is anticipated to register the highest CAGR during the forecast period.
• Based on indication, the late stage chronic kidney disease drug market is segmented into late stage chronic kidney disease-induced hyperparathyroidism, late stage chronic kidney disease-induced hyperphosphatemia, and late stage chronic kidney disease-induced hyperkalemia. The late stage chronic kidney disease-induced hyperparathyroidism segment held the largest market share in 2023, whereas the same segment is projected to register the highest CAGR during the forecast period.
• Based on distribution channels, the late stage chronic kidney disease drugs market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment held the largest market share in 2023. However, online pharmacy is estimated to register the highest CAGR of 12.2% in the market during the forecast period.

Late Stage Chronic Kidney Disease Drugs Market Share Analysis by Geography

The geographic scope of the Late Stage Chronic Kidney Disease Drugs market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America/South & Central America.

The North America late stage chronic kidney disease drugs market is segmented into the US, Canada, and Mexico. The US held the largest share of the North American late stage chronic kidney disease drugs market in 2023. The projected growth of the late stage chronic kidney disease drugs market in North America is the presence of key market players, growing end-stage renal disease and chronic kidney disease, and extensive R&D directed by various academic and research institutes. CKD is a major public health burden both nationally and internationally. The global mean prevalence of CKD is 13.4%, and within Canada, most recent estimates suggest at least 4 million people have the disease. CKD poses a significant burden on the healthcare system: recent estimates of healthcare costs for Canadians with CKD exceed US$40 billion annually. This condition is more common among people with hypertension, cardiovascular disease, diabetes, and others who have adverse health outcomes.

Late Stage Chronic Kidney Disease Drugs Market Regional Insights

The regional trends and factors influencing the Late Stage Chronic Kidney Disease Drugs Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Late Stage Chronic Kidney Disease Drugs Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Late Stage Chronic Kidney Disease Drugs Market Report Scope

Late Stage Chronic Kidney Disease Drugs Market Players Density: Understanding Its Impact on Business Dynamics

The Late Stage Chronic Kidney Disease Drugs Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Late Stage Chronic Kidney Disease Drugs Market are:

1. AbbVie Inc.
2. Amgen
3. AstraZeneca
4. Sanofi
5. Kyowa Kirin Co., Ltd.
6. Takeda Pharmaceutical Company Limited

Disclaimer: The companies listed above are not ranked in any particular order.

Late Stage Chronic Kidney Disease Drugs Market News and Recent Developments

The Late Stage Chronic Kidney Disease Drugs market is evaluated by gathering qualitative and quantitative data from primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for Late Stage Chronic Kidney Disease Drugs:

• Sun Pharma and Bayer jointly agreed to market a drug for treating chronic kidney disease. Under the terms of the agreement, Bayer has granted Sun Pharma non-exclusive rights to market and distribute a second Finerenone product under the brand name Lyvelsa. (Bayer /Press Release, January 2024)
• Boehringer Ingelheim with Eli Lilly and Company announced FDA approval for Jardiance (empagliflozin) tablets, examined as a potential treatment to reduce the risk of kidney disease development and cardiovascular death in adults with chronic kidney disease (CKD). (Source: Boehringer Ingelheim International GmbH, Press Release, October 2023)

Late Stage Chronic Kidney Disease Drugs Market Report Coverage and Deliverables

The “Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

• Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Market dynamics such as drivers, restraints, and key opportunities
• Key future trends
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
• Detailed company profiles